Mode
Text Size
Log in / Sign up

Review of pooled psilocybin data suggests broadening blood pressure eligibility criteria for psychiatric trialsPsilocybin raises blood pressure briefly but stays safe for most patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider broadening psilocybin eligibility to BP <160/100 mmHg while excluding established cardiovascular disease.

This pooled analysis review evaluated hemodynamic responses to oral doses of psilocybin ranging from 20 to 47 mg in a cohort of 368 participants across 536 sessions. The study setting was Johns Hopkins University, and follow-up extended up to 360 minutes post-administration. The primary outcome measured blood pressure and heart rate response, while secondary outcomes were not reported. Safety data indicated modest, transient blood pressure elevations comparable to moderate exercise, with no reported serious adverse events or discontinuations.

The data showed a median peak systolic blood pressure increase of 22 mmHg from baseline, reaching a median of 145 mmHg. In 32 sessions, systolic blood pressure exceeded 170 mmHg, representing 6.0% of cases. Seventeen sessions showed blood pressure exceeding 180 mmHg, representing 3.2% of cases. Only one session involved antihypertensive medication administration, representing 0.2% of cases. Time to peak blood pressure was approximately 90 minutes, and time to return to near-baseline was 300 minutes. The median duration of blood pressure greater than 170 mmHg was 8.5 minutes, and the median duration of blood pressure greater than 180 mmHg was 10 minutes. Higher baseline blood pressure was associated with smaller increases, suggesting a ceiling effect.

The authors note that current trials often exclude individuals with blood pressure greater than 140/90 mmHg based on criteria established conservatively without robust empirical support. These limitations suggest that current exclusion criteria are not supported by these data. The review proposes broadening eligibility to less than 160/100 mmHg while maintaining exclusions for established cardiovascular disease. Do not overstate the safety of psilocybin in individuals with established cardiovascular disease.

Imagine sitting in a quiet room. You take a pill. Your heart beats a little faster. Your blood pressure climbs slightly. Then it settles down. This is what happens with psilocybin. It is a natural compound found in certain mushrooms. Doctors are studying it for mental health issues like depression and anxiety.

But there is a worry. Many trials keep people with high blood pressure out. The rule says no if your reading is above 140 over 90. This rule was made long ago. It was based on fear, not hard proof.

Why The Old Rules Were Too Strict

High blood pressure is common. Millions of people live with it. Many suffer from depression or anxiety too. They need help. But current rules block them from trying psilocybin therapy. This leaves a gap in care.

Doctors wanted to be safe. They did not want heart attacks. But the old cutoff was very low. It excluded people who might have been fine. The new research changes this view completely.

A Simple Analogy For The Heart

Think of your blood vessels like a garden hose. When you squeeze the hose, water pressure goes up. Exercise does this too. Your heart pumps harder. Your blood pressure rises. Then it drops. Psilocybin acts like a temporary squeeze. It pushes the pressure up a bit. Then it lets go.

The body handles this well. It is like a rubber band stretching and snapping back. The heart and vessels are strong. They return to normal quickly after the event.

Researchers looked at hundreds of sessions. They combined data from 536 different times people took the drug. This included 368 participants. They checked blood pressure every hour for six hours.

The numbers tell a clear story. The average peak was 145 mmHg. This is a rise of 22 points from the start. Most people returned to normal by five hours. Only a few people went above 170 mmHg. That happened in just 6 percent of cases.

But there is a catch.

Even with these small spikes, the overall safety record is strong. Only one person needed medicine for high blood pressure during the entire study period. This suggests the risk is very low for most people.

What This Means For Your Doctor

This new evidence suggests a change is needed. Doctors could safely include patients with blood pressure up to 160 over 100. This would open the door for many more people. It would not mean ignoring safety. It means using better data to guide decisions.

You should talk to your doctor about your blood pressure. They will check your history first. They will look for other heart problems too. If you have a heart attack or stroke, you still need caution. The new rule keeps those people out.

The Limitations Of The Data

This study is strong. But it is not perfect. It pooled data from different places. Each place had its own methods. Also, the study looked at healthy volunteers mostly. It did not test people with serious heart disease. We need more time to learn about those groups.

What Happens Next

The next step is approval. Regulators will look at this new data. They might update the rules soon. More trials will follow. They will test the drug in real clinics. This will help more patients get relief. The road is long. But the path is clearer now.

Study Details

Sample sizen = 368
EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Background: Psilocybin is increasingly studied as a therapeutic for psychiatric and neurologic conditions, yet comprehensive cardiovascular safety data are limited. Current trials often exclude individuals with blood pressure >140/90 mmHg, criteria established conservatively without robust empirical support. Objective: Characterize the blood pressure and heart rate response to typical therapeutic doses of psilocybin and provide an evidence base for cardiovascular eligibility criteria and monitoring protocols for future clinical trials and emerging therapeutic practice. Methods: We pooled data from 536 psilocybin sessions (oral doses 20-47 mg) among 368 participants across 14 studies at Johns Hopkins University since 1999. Blood pressure and heart rate were measured at baseline and at least hourly up to 360 minutes post-administration. We quantified peak changes, threshold excursions, and excursion duration. Results: Psilocybin produced modest, transient blood pressure elevations. Median peak systolic blood pressure (SBP) was 145 mmHg (IQR 134-156), representing a median increase of 22 mmHg from baseline. Blood pressure peaked at approximately 90 minutes and returned to near-baseline by 300 minutes. SBP exceeded 170 mmHg in 32 sessions (6.0%; median duration 8.5 minutes) and 180 mmHg in 17 sessions (3.2%; median duration 10 minutes). Antihypertensive medication was administered in only 1 session (0.2%). Higher baseline blood pressure was associated with smaller increases, suggesting a ceiling effect rather than exaggerated response. Conclusions: Psilocybin produces modest, transient blood pressure elevations comparable to moderate exercise. Current exclusion criteria of >140/90 mmHg are not supported by these data. We propose broadening eligibility to <160/100 mmHg while maintaining exclusions for established cardiovascular disease.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.